sorafenib has been researched along with Kidney Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, CH; Chen, LH; Chen, Y; Chen, YT; Cheng, HT; Huang, HC; Huang, KH; Huang, KW; Jin, PR; Juang, IP; Lee, TY; Liao, YH; Lin, SL; Lin, TC; Liu, ZY; Sheng, YH; Su, CT; Sung, YC; Wang, HC; Wang, J | 1 |
| Iwasaki, H; Masudo, K; Nakayama, H; Sakai, R; Suganuma, N; Takasaki, H; Toda, S; Yamazaki, H | 1 |
| Audard, V; Bahleda, R; Baumelou, A; Bouachi, K; Bourry, E; Izzedine, H; Khayat, D; Lang, P; Mangier, M; Massard, C; Ollero, M; Ory, V; Pawlak, A; Péchoux, C; Sahali, D; Sendeyo, K; Soria, JC; Zhang, SY | 1 |
| Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J | 1 |
| Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
| Eberhardt, W; Grubert, M; Hense, J; Hilger, RA; Kredtke, S; Richly, H; Scheulen, ME; Schuler, M; Thyssen, D | 1 |
| Chen, HX; Cleck, JN | 1 |
3 review(s) available for sorafenib and Kidney Diseases
| Article | Year |
|---|---|
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Retrospective Studies; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2014 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
6 other study(ies) available for sorafenib and Kidney Diseases
| Article | Year |
|---|---|
Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis.
Topics: Animals; Collagen; Disease Models, Animal; Drug Carriers; Fibrosis; Kidney; Kidney Diseases; Ligands; Mice; Mice, Inbred C57BL; Myofibroblasts; Nanoparticles; Sorafenib; Ureteral Obstruction | 2022 |
Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Topics: Aged; Drug Substitution; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Iodine Radioisotopes; Kidney Diseases; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Radiation Tolerance; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; Binding Sites; Biomarkers; Carrier Proteins; Case-Control Studies; Cell Line; Female; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Nephrosis, Lipoid; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Sorafenib; Thrombotic Microangiopathies; Transcription Factor RelA; Transcription, Genetic; Transfection; Vascular Endothelial Growth Factors; Young Adult | 2014 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Specimen Collection; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kidney Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Time Factors | 2009 |